A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HLX3901 in Patients With Advanced SCLC or NEC
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This study is an open-label first-in-human phase I clinical study to evaluate the safety, tolerability, and pharmacokinetic characteristics of HLX3901 in patients with Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek 18-75 lat
- •Potwierdzony rozpoznaniem raka płuc drobnokomórkowego lub nowotworu neuroendokrynnego
- •Wcześniejsze leczenie chemioterapią opartą na platynie, które nie zadziałało lub spowodowało niepożądane objawy
- •Co najmniej jedno widoczne na badaniach ognisko nowotworu
- •Dobry ogólny stan zdrowia (ECOG 0-1)
- •Spodziewany czas przeżycia dłuższy niż 3 miesiące
- •Wyleczenie ze skutków ubocznych poprzednich terapii
- •Zgoda na przekazanie próbki guza do badań
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 75 Years
- Last updated (source)
- July 8, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (2)
Peking Union Medical College Hospital
Beijing, China
Shanghai Chest Hospital
Shanghai, China
Trial contact
Mengzhao Wang, Dr
Shun Lu, Dr
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/9/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.